Needham analyst Ami Fadia maintained a Buy rating on Axsome Therapeutics yesterday and set a price target of $225.00.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Ami Fadia has given his Buy rating due to a combination of factors related to Axsome Therapeutics’ recent commercial performance. In her view, the company’s flagship products Auvelity and Sunosi are demonstrating stronger-than-anticipated revenue momentum, with preliminary fourth-quarter and full-year 2025 sales modestly exceeding market expectations. This outperformance versus consensus indicates robust demand trends and supports a more favorable outlook for the company’s top line.
While Symbravo’s uptake is progressing more gradually and came in below Street estimates, Fadia appears to view it as a newer launch that is building at a measured but consistent pace rather than a key driver at this stage. On balance, the better-than-expected contributions from Auvelity and Sunosi more than offset Symbravo’s slower ramp, reinforcing the growth narrative. As a result, she anticipates a constructive market reaction to the pre-announcement and sees the current setup as supportive of a Buy recommendation on AXSM.